At Inaphaea BioLabs, we are committed to understanding our clients’ drug candidates during the discovery and preclinical phases of development within the oncology space.
In recognition of Gynaecological Cancer Awareness Month, the Inaphaea team explores the potential of patient derived cells for gynaecological cancers.
Gynaecological cancers, including ovarian, endometrial, and fallopian cancers, represent some of the most challenging areas in oncology, due to the complexities involved in their detection and treatment. Developing effective therapies therefore requires a deep understanding of how these diseases work.
The impact of hypoxia
Hypoxia within tumours is a key driver in cancer progression. In the case of ovarian cancer, hypoxia not only accelerates tumour growth but also contributes to the development of metastatic disease. This makes it a crucial factor to consider when developing and testing new therapeutic candidates.
Gynecological cancers and our PDC portfolio
To better understand how drug candidates perform under different conditions, we offer testing services under both normoxia (normal oxygen) and hypoxia (low oxygen) across our range of 470 patient derived cell lines. This includes over 80 ovarian cancer-specific lines, as well as several endometrial and fallopian cancer PDCs.
Our PDCs can be purchased for use in your own lab, with your own scientists, team, and facilities, or they can be used in Inaphaea’s lab with our services packages. Inaphaea has established protocols or can work with clients to develop bespoke protocols to evaluate drug activity in 2D and 3D cell culture and can include co-culture with immune cells. We also offer high throughput candidate screening and lead selection.
To find out more about our patient derived cells and how they compare to other oncology models, click here.
Understanding and advancing oncology drug development
Inaphaea is at the forefront of harnessing the power of PDCs, and we are dedicated to comprehensively understanding our drug candidates during the discovery and preclinical phases of development. Our goal is to support decision-making in translational drug development for therapeutic areas within oncology.
To discuss your drug development project with our lab team, please get in touch.